Abcam, ab286675, Human KMT2A knockout A549 cell line

Size: 1000000Cells / vial / 2 x 1000000Cells / vial
KMT2A KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control available. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Form:LiquidSee storage information,
Knockout validation:Next Generation Sequencing,
Disease:Carcinoma

Product details:
Although we aim to provide customers with a homozygous clone, feasibility will be dependent on the biology of the protein. Should only heterozygous edits be achieved, you will be notified of the outcome and be asked to confirm whether the cell line is acceptable. All clones will be accompanied with DNA sequencing data, and the mutation description.
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-KMT2A, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The KMT2A protein also known as MLL (Mixed-Lineage Leukemia) is a large protein with a molecular weight of approximately 431 kDa. This protein functions as a histone methyltransferase which means it adds methyl groups to histone proteins specifically at the lysine 4 position on histone H3 (H3K4). This modification impacts chromatin structure and gene expression. KMT2A/MLL is chiefly expressed in hematopoietic stem cells and various tissue types indicating its broad role in regulation across the body. The protein features a SET domain a characteristic motif for proteins involved in chromatin modification.
Biological function summary
This methyltransferase plays a significant role in regulating gene expression required for normal hematopoietic development and maintenance. KMT2A/MLL forms part of the multi-protein complex called COMPASS-like complex which is essential for its function in methylation activity. Within this complex it associates with other proteins like WDR5 RBBP5 and ASH2L that collaborate to control transcriptional elongation. KMT2A/MLL is also involved in maintaining the expression of various homeobox (HOX) genes which are critical for embryonic development and cell differentiation.
Pathways
KMT2A/MLL plays an integral role in hematopoietic and developmental signaling pathways. One key pathway is the Wnt signaling pathway important for regulating stem cell pluripotency and cell fate decisions. Another pathway is the Notch signaling pathway important for cell differentiation processes. KMT2A interacts with proteins within these pathways such as CXXC1 which links it to the DNA binding properties required for regulating target gene expression.
KMT2A/MLL is closely linked to leukemia notably acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). A significant factor contributing to these associations is the gene fusions involving KMT2A often created during chromosomal translocations which result in oncogenic activation. In these leukemias it can form fusion proteins like MLL-AF4 impacting the normal regulatory activities of KMT2A. This aberrant interaction with proteins such as MEN1 can contribute to oncogenic processes by altering transcription and leading to uncontrolled cell growth.